Fosfomycin Synergy In Vitro with Amoxicillin, Daptomycin, and Linezolid against Vancomycin-Resistant Enterococcus faecium from Renal Transplant Patients with Infected Urinary Stents
Fosfomycin Synergy In Vitro with Amoxicillin, Daptomycin, and Linezolid against Vancomycin-Resistant Enterococcus faecium from Renal Transplant Patients with Infected Urinary Stents
复制标题
DOI：
10.1128/aac.02099-12
复制
发表时间：
2013-03-01
影响因子：
4.9
通讯作者：
Rose, Warren E.
中科院分区：
文献类型：
--
作者：
Descourouez, Jillian L.;Jorgenson, Margaret R.;Rose, Warren E.
尽管体外和临床数据有限，但磷霉素是万古霉素耐药肠球菌（VRE）感染的潜在选择。在本研究中，根据MIC（50）和MIC（90），32株来自肾移植患者泌尿系支架感染的VRE分离株对磷霉素、达托霉素和利奈唑胺敏感，对阿莫西林、米诺环素和呋喃妥因耐药。磷霉素在0.5至16倍MIC（32至2，048 μ g/ml）时具有抑菌作用;当磷霉素与达托霉素联合使用时产生协同作用（2.8至3.9 log（10）CFU/ml杀灭; P
Fosfomycin is a potential option for vancomycin-resistant enterococcus (VRE) infections despite limited in vitro and clinical data. In this study, 32 VRE isolates from renal transplant patients with urinary stent infections were susceptible to fosfomycin, daptomycin, and linezolid and resistant to amoxicillin, minocycline, and nitrofurantoin based on their MIC(50)s and MIC(90)s. Fosfomycin was bacteriostatic at 0.5 to 16x the MIC (32 to 2,048 mu g/ml); synergy occurred when fosfomycin was combined with daptomycin (2.8 to 3.9 log(10) CFU/ml kill; P